These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery. Strebhardt K; Becker S; Matthess Y Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688 [TBL] [Abstract][Full Text] [Related]
9. Identification of novel, potent and selective inhibitors of Polo-like kinase 1. Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702 [TBL] [Abstract][Full Text] [Related]
10. Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents. Qi B; Zhong L; He J; Zhang H; Li F; Wang T; Zou J; Lin YX; Zhang C; Guo X; Li R; Shi J J Med Chem; 2019 Sep; 62(17):7697-7707. PubMed ID: 31381325 [TBL] [Abstract][Full Text] [Related]
11. Single step synthesis of new fused pyrimidine derivatives and their evaluation as potent Aurora-A kinase inhibitors. Shaaban MR; Saleh TS; Mayhoub AS; Farag AM Eur J Med Chem; 2011 Sep; 46(9):3690-5. PubMed ID: 21664013 [TBL] [Abstract][Full Text] [Related]
12. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Lens SM; Voest EE; Medema RH Nat Rev Cancer; 2010 Dec; 10(12):825-41. PubMed ID: 21102634 [TBL] [Abstract][Full Text] [Related]
13. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors. Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677 [TBL] [Abstract][Full Text] [Related]
14. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets. Krushkal J; Silvers T; Reinhold WC; Sonkin D; Vural S; Connelly J; Varma S; Meltzer PS; Kunkel M; Rapisarda A; Evans D; Pommier Y; Teicher BA Clin Epigenetics; 2020 Jun; 12(1):93. PubMed ID: 32586373 [TBL] [Abstract][Full Text] [Related]
15. [The serine/threonine kinases that control cell cycle progression as therapeutic targets]. Diallo A; Prigent C Bull Cancer; 2011 Nov; 98(11):1335-45. PubMed ID: 22020767 [TBL] [Abstract][Full Text] [Related]
16. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening. Lu S; Sun SL; Liu HC; Chen YD; Yuan HL; Gao YP; Yang P; Lu T Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481 [TBL] [Abstract][Full Text] [Related]
17. Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases. Markant SL; Esparza LA; Sun J; Barton KL; McCoig LM; Grant GA; Crawford JR; Levy ML; Northcott PA; Shih D; Remke M; Taylor MD; Wechsler-Reya RJ Cancer Res; 2013 Oct; 73(20):6310-22. PubMed ID: 24067506 [TBL] [Abstract][Full Text] [Related]
18. Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present). Bian S; Zhang R; Nie J; Zhu M; Xie Z; Liao C; Wang Q Expert Opin Ther Pat; 2024 Sep; 34(9):789-806. PubMed ID: 38994687 [TBL] [Abstract][Full Text] [Related]
19. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe. Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386 [TBL] [Abstract][Full Text] [Related]
20. Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold. Lv X; Yang X; Zhan MM; Cao P; Zheng S; Peng R; Han J; Xie Z; Tu Z; Liao C Eur J Med Chem; 2019 Dec; 184():111769. PubMed ID: 31629162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]